Euroapi (EAPI) Stock Overview
Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
EAPI Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Euroapi S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.02 |
| 52 Week High | €3.44 |
| 52 Week Low | €0.92 |
| Beta | 0.96 |
| 1 Month Change | -26.06% |
| 3 Month Change | -32.72% |
| 1 Year Change | -62.37% |
| 3 Year Change | -91.46% |
| 5 Year Change | n/a |
| Change since IPO | -92.48% |
Recent News & Updates
Narrative Update • Aug 04
EAPI: Reset Expectations And Lower P E Multiple Could Support Rebound
Analysts have trimmed their fair value estimate for Euroapi, with the updated €1.20 target down from €1.48. This is aligned with recent Street research that reduced the official price target to €1.70 from €2.90 on revised expectations for growth, margins and future P/E levels.Analysis Article • Aug 02
Euroapi S.A. (EPA:EAPI) Just Reported, And Analysts Assigned A €1.20 Price Target
Shareholders in Euroapi S.A. ( EPA:EAPI ) had a terrible week, as shares crashed 20% to €0.98 in the week since its...
Narrative Update • Jul 14
EAPI: Execution On Efficiency Plans Could Unlock Upside Under Reset Expectations
Analysts have reduced their Euroapi price target to €1.70 from €2.90, citing updated assumptions around revenue growth, profit margins, the discount rate and future P/E expectations. Analyst Commentary Recent commentary around Euroapi has focused on how the lower €1.70 price target aligns with revised expectations for revenue, margins and valuation multiples.Narrative Update • Jun 30
EAPI: Reset Expectations And Higher Future P/E Could Support Rebound
Analysts have reduced their fair value estimate for Euroapi, cutting the price target from €2.00 to about €1.48. This is broadly in line with a recent move by the Street to bring targets down toward €1.70 as they factor in weaker revenue growth expectations and revised profitability assumptions alongside a higher future P/E multiple.Recent updates
Narrative Update • Aug 04
EAPI: Reset Expectations And Lower P E Multiple Could Support Rebound
Analysts have trimmed their fair value estimate for Euroapi, with the updated €1.20 target down from €1.48. This is aligned with recent Street research that reduced the official price target to €1.70 from €2.90 on revised expectations for growth, margins and future P/E levels.Analysis Article • Aug 02
Euroapi S.A. (EPA:EAPI) Just Reported, And Analysts Assigned A €1.20 Price Target
Shareholders in Euroapi S.A. ( EPA:EAPI ) had a terrible week, as shares crashed 20% to €0.98 in the week since its...Narrative Update • Jul 14
EAPI: Execution On Efficiency Plans Could Unlock Upside Under Reset Expectations
Analysts have reduced their Euroapi price target to €1.70 from €2.90, citing updated assumptions around revenue growth, profit margins, the discount rate and future P/E expectations. Analyst Commentary Recent commentary around Euroapi has focused on how the lower €1.70 price target aligns with revised expectations for revenue, margins and valuation multiples.Narrative Update • Jun 30
EAPI: Reset Expectations And Higher Future P/E Could Support Rebound
Analysts have reduced their fair value estimate for Euroapi, cutting the price target from €2.00 to about €1.48. This is broadly in line with a recent move by the Street to bring targets down toward €1.70 as they factor in weaker revenue growth expectations and revised profitability assumptions alongside a higher future P/E multiple.
Narrative Update • Jun 16
EAPI: Revenue Contraction And Margin Pressure Will Continue To Restrain Future Earnings
Euroapi's analyst price target has been cut by €1.20 to €1.70, as analysts point to updated expectations for revenue contraction, profit margins, and a lower future P/E multiple. Analyst Commentary on Euroapi The latest research on Euroapi highlights a more cautious stance, with a reduced price target and a Neutral rating that suggests limited conviction in a strong near term recovery.Narrative Update • Jun 02
EAPI: Weaker Demand And Margin Pressure Will Drag On Future Earnings
Analysts have cut Euroapi's price target sharply, with recent revisions moving from €2.90 to a range of €1.70 and €1. This reflects more cautious assumptions on revenue trends, margins and a higher P/E multiple applied to the stock.Narrative Update • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.Narrative Update • Apr 22
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.Narrative Update • Apr 08
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.Narrative Update • Mar 25
EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality
Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.Narrative Update • Mar 10
EAPI: Weaker 2025 Guidance Will Pressure Margins And Future Earnings Quality
Analysts have cut their Euroapi price target from €2 to €1, reflecting updated assumptions that now factor in lower revenue growth expectations, much slimmer profit margins, and a significantly higher future P/E multiple. Analyst Commentary Recent price target revisions point to a cautious stance from bearish analysts, who appear focused on execution risks and the implications for Euroapi's valuation.Narrative Update • Feb 24
EAPI: Lower 2025 Guidance And Reduced Multiple Will Shape Return Profile
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing updated assumptions on modest revenue growth, slightly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent research points to a more cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.Narrative Update • Feb 09
EAPI: Lower 2025 Outlook And Cautious Stance Will Shape Return Profile
Analysts have lowered their price target on Euroapi from €2.50 to €2, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that collectively suggest a more cautious valuation stance. Analyst Commentary Bearish analysts have recently cut their price target on Euroapi from €2.50 to €2.Narrative Update • Jan 25
EAPI: Execution Risks And Lower Outlook Will Shape Future Return Profile
Narrative update Analysts have trimmed their price target on Euroapi by €0.50 to €2.00, citing updated assumptions on revenue growth, profit margins and forward P/E that keep their stance cautious on the shares. Analyst Commentary Recent research has reinforced a cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.00.Narrative Update • Jan 10
EAPI: Lower Profitability Assumptions And New Partnership Will Shape Future Returns
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing softer assumptions around revenue growth, profit margins and a higher future P/E multiple as the key drivers of the reset. Analyst Commentary Bearish analysts are signalling a cautious stance on Euroapi by aligning around a lower price target of €2, narrowed from €2.50.Narrative Update • Dec 19
EAPI: Higher Discount Rate Will Outweigh Benefits From New Corticosteroid Partnership
Analysts have slightly reduced their Euroapi price target, reflecting a modest reassessment of fair value. This adjustment accounts for a higher discount rate, even as long term profit margin assumptions edge up and revenue declines appear marginally less severe.Analysis Article • Dec 18
Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €2.68 Euroapi's €2.40 share...Analysis Article • Dec 18
Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%
Euroapi S.A. ( EPA:EAPI ) shareholders that were waiting for something to happen have been dealt a blow with a 26...Analysis Article • Oct 03
Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Aug 02
Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
It's been a mediocre week for Euroapi S.A. ( EPA:EAPI ) shareholders, with the stock dropping 12% to €2.79 in the week...
New Narrative • Mar 31
Capacity Expansion And Efficiency Improvements Will Shape Future Success
Euroapi focuses on high-margin differentiated APIs and CDMO services to boost sustainable revenue and profit margins through strategic project expansions.Analysis Article • Mar 06
Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...Analysis Article • Oct 04
Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price
Key Insights The projected fair value for Euroapi is €2.62 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • Jul 29
There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise
Euroapi S.A. ( EPA:EAPI ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...Analysis Article • May 24
Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Euroapi S.A. ( EPA:EAPI ) shares would be relieved that the share price has rebounded 29% in the last...Analysis Article • Apr 10
Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Mar 03
Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
The Euroapi S.A. ( EPA:EAPI ) share price has fared very poorly over the last month, falling by a substantial 31%. For...Analysis Article • Mar 02
Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Euroapi S.A. ( EPA:EAPI ) shares in the week since it released its yearly report, with...Analysis Article • Dec 21
A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €5.03 With €5.47 share price...Analysis Article • Aug 04
Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...Shareholder Returns
| EAPI | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -18.1% | -5.6% | 1.8% |
| 1Y | -62.4% | -4.6% | 8.3% |
Return vs Industry: EAPI underperformed the French Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: EAPI underperformed the French Market which returned 7.9% over the past year.
Price Volatility
| EAPI volatility | |
|---|---|
| EAPI Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in FR Market | 10.1% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: EAPI's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: EAPI's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 2,961 | David Seignolle | www.euroapi.com/en |
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; and steroids and hormones substances. It also provides API solutions, such as vitamin B12, prostaglandins, corticoids and hormones, anti-infectives, opiates and controlled substances, small and complex molecules, and intermediates and reagents.
Euroapi S.A. Fundamentals Summary
| EAPI fundamental statistics | |
|---|---|
| Market cap | €97.06m |
| Earnings (TTM) | -€324.20m |
| Revenue (TTM) | €794.60m |
0.1x
P/S Ratio-0.3x
P/E RatioIs EAPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EAPI income statement (TTM) | |
|---|---|
| Revenue | €794.60m |
| Cost of Revenue | €670.50m |
| Gross Profit | €124.10m |
| Other Expenses | €448.30m |
| Earnings | -€324.20m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.39 |
| Gross Margin | 15.62% |
| Net Profit Margin | -40.80% |
| Debt/Equity Ratio | 13.5% |
How did EAPI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/04 05:50 |
| End of Day Share Price | 2026/08/04 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Euroapi S.A. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Steven Smith | Bernstein |
| Patrick Andrew Wood | BofA Global Research |
| Fynn Scherzler | Deutsche Bank |